BE2017C056I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C056I2
BE2017C056I2 BE2017C056C BE2017C056C BE2017C056I2 BE 2017C056 I2 BE2017C056 I2 BE 2017C056I2 BE 2017C056 C BE2017C056 C BE 2017C056C BE 2017C056 C BE2017C056 C BE 2017C056C BE 2017C056 I2 BE2017C056 I2 BE 2017C056I2
Authority
BE
Belgium
Application number
BE2017C056C
Original Assignee
Wyeth Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C056(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc
Publication of BE2017C056I2 publication Critical patent/BE2017C056I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
BE2017C056C 2001-10-11 2017-11-23 BE2017C056I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US40693402P 2002-08-30 2002-08-30
EP02804818.9A EP1442047B1 (fr) 2001-10-11 2002-10-11 Nouvelle compositions immunogenes utilisees pour la prevention et le traitement de la meningococcie

Publications (1)

Publication Number Publication Date
BE2017C056I2 true BE2017C056I2 (fr) 2022-02-01

Family

ID=27668840

Family Applications (3)

Application Number Title Priority Date Filing Date
BE2017C055C BE2017C055I2 (fr) 2001-10-11 2017-11-23
BE2017C056C BE2017C056I2 (fr) 2001-10-11 2017-11-23
BE2017C057C BE2017C057I2 (fr) 2001-10-11 2017-11-23

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE2017C055C BE2017C055I2 (fr) 2001-10-11 2017-11-23

Family Applications After (1)

Application Number Title Priority Date Filing Date
BE2017C057C BE2017C057I2 (fr) 2001-10-11 2017-11-23

Country Status (19)

Country Link
US (13) US8101194B2 (fr)
EP (14) EP2348036B1 (fr)
JP (6) JP2005515771A (fr)
KR (4) KR101099916B1 (fr)
CN (4) CN105617372A (fr)
AU (3) AU2009213040C1 (fr)
BE (3) BE2017C055I2 (fr)
BR (1) BRPI0212999B8 (fr)
CA (5) CA2918207C (fr)
DK (10) DK2348036T3 (fr)
ES (14) ES2532640T3 (fr)
FR (4) FR15C0056I2 (fr)
HK (2) HK1178429A1 (fr)
IL (5) IL161052A0 (fr)
LU (4) LU92786I2 (fr)
MX (3) MX339524B (fr)
NL (3) NL300896I2 (fr)
PT (10) PT2332961T (fr)
WO (1) WO2003063766A2 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261343A3 (fr) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
CA2929348A1 (fr) 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Compositions a base de combinaisons de neisseria
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
BRPI0107679B8 (pt) 2000-01-17 2021-05-25 Chiron Spa composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
CN100339482C (zh) 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2351579B1 (fr) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ATE552844T1 (de) 2003-01-30 2012-04-15 Novartis Ag Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
BR122017002991B1 (pt) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
EP2425855A1 (fr) 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
SI1896065T2 (sl) * 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Postopek za pripravo cepiv
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
BRPI0715360B8 (pt) 2006-07-27 2022-01-04 Wyeth Corp método para a produção de uma proteína recombinante; método para a produção de uma proteína 2086 meningocócica recombinante (p2086); e composição
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2886551A3 (fr) 2008-02-21 2015-09-23 Novartis AG Polypeptides fHbp méningococciques
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2756522C (fr) 2009-03-24 2018-06-26 Novartis Ag Proteine de liaison du facteur h meningococcique utilisee comme adjuvant
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
EP2443250B8 (fr) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA Dosages haut débit de bactéricides opsoniques et dépendant d'anticorps à médiation par le complément
CA2772104A1 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des sequences fhbp a meningocoques
BR112012004276A2 (pt) 2009-08-27 2017-10-24 Novartis Ag adjuvante compreendendo alumínio, oligonucleotídeo e policátion
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
MX2012004850A (es) 2009-10-27 2012-05-22 Novartis Ag Polipeptidos fhbp meningococicos modificados.
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
CN102933229A (zh) 2010-06-04 2013-02-13 惠氏有限责任公司 疫苗制剂
WO2011161653A1 (fr) 2010-06-25 2011-12-29 Novartis Ag Associations de protéines de liaison du facteur h méningococcique
CN103189071A (zh) * 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2613805B1 (fr) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA MENINGOCOQUE SUREXPRIMANT NADA ET/OU NHBA ET DES 
VESICULES DE MEMBRANE EXTERNE DÉRIVÉS DE CELLE-CI
WO2012032489A1 (fr) 2010-09-10 2012-03-15 Wyeth Llc Variants non-lipidiques des antigènes orf 2086 de neisseria meningitidis
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
WO2012153302A1 (fr) 2011-05-12 2012-11-15 Novartis Ag Antipyrétiques pour améliorer la tolérabilité de vaccins à base de vésicules
WO2013098589A1 (fr) 2011-12-29 2013-07-04 Novartis Ag Combinaisons avec adjuvant de protéines méningococciques liant le facteur h
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
WO2013132043A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Vaccins combinés comprenant des agonistes du tlr4
WO2013132040A2 (fr) 2012-03-08 2013-09-12 Novartis Ag Dosage de puissance in vitro pour des vaccins méningococciques à base de protéine
AU2013229063B2 (en) * 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2644340C2 (ru) 2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х
WO2014016152A1 (fr) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Utilisation du cd147 comme récepteur pour l'adhésion impliquant les pili des méningocoques à l'endothélium vasculaire
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
CA2903716C (fr) 2013-03-08 2019-04-09 Pfizer Inc. Polypeptides immunogenes de fusion
AU2014296027A1 (en) 2013-08-02 2016-02-04 Children's Hospital & Research Center At Oakland Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
NZ766005A (en) 2014-07-23 2024-03-22 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP3263695A1 (fr) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Compositions immunogènes
CN106434720A (zh) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 提高脑膜炎奈瑟菌fHBP蛋白表达的方法
CA3035320A1 (fr) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccins contre neisseria gonorrhoeae
EP4309670A2 (fr) 2016-09-02 2024-01-24 Sanofi Pasteur, Inc. Vaccin contre neisseria meningitidis
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN111133378B (zh) 2017-09-28 2021-04-23 富士胶片株式会社 摄像装置、信息获取方法及记录介质
WO2019065554A1 (fr) * 2017-09-28 2019-04-04 富士フイルム株式会社 Dispositif de capture d'image, procédé d'acquisition d'informations et programme d'acquisition d'informations
TWI687696B (zh) * 2019-06-26 2020-03-11 國立中興大學 回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
CN114681601A (zh) * 2020-12-31 2022-07-01 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
CA3211240A1 (fr) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Vaccin recombinant meningococcique b
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023138914A1 (fr) 2022-01-24 2023-07-27 Koninklijke Philips N.V. Détermination de vitesse d'onde de pouls par co-enregistrement de données intravasculaires et d'une image extraluminale, et systèmes, dispositifs et procédés associés
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (fr) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Composition immunogène à adjuvant contre neisseria meningitidis b

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (de) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0232262A4 (fr) 1985-08-15 1989-09-19 Stauffer Chemical Co Microorganisme producteur de tryptophane.
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
CA1315719C (fr) 1988-02-05 1993-04-06 Arthur Bank Lignees cellulaires utilisees pour l'encapsidation de retrovirus et modes d'utilisation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA1339354C (fr) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Retrovirus recombinants avec spectres d'activite amphotropes et ecotropes
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
DK0606921T3 (da) * 1989-03-09 2000-09-04 American Cyanamid Co Fremgangsmåde til isolering af Haemophilus influenzae protein E
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (fr) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (fr) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Vecteurs eucaryotiques a base de virus adeno-associes (aav)
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
JPH0453645U (fr) * 1990-09-12 1992-05-07
BR9106879A (pt) 1990-09-25 1993-07-20 Cantab Pharma Res Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
AU681572B2 (en) 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (fr) * 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. HOLOENZYME ADN POLYMERASE III et E. COLI ET SOUS-UNITES
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
CA2158148A1 (fr) 1993-03-19 1994-09-29 Stephen Charles Inglis Virus defectif mutant non retroviral (par ex. hsv), utilise comme vaccin
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
WO1995007358A1 (fr) 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Transfert efficace de genes dans des lymphocytes primaires
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi) 1994-02-21 1997-04-10 Arto Remes Laite inkontinenssihoitoa varten
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (fr) 1994-03-25 1995-10-05 The Uab Research Foundation Composition et methodes d'obtention de cellules productrices de virus de recombinaison isogeniques
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
JPH10501963A (ja) 1994-04-15 1998-02-24 ターゲテッド ジェネティクス コーポレイション 遺伝子送達融合タンパク質
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
EP0710118B1 (fr) * 1994-04-20 1998-11-25 U.S. Department Of The Army Vaccin contre les infections par des bacteries gram-negatives
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU6043396A (en) 1995-06-05 1996-12-24 University Of Alabama At Birmingham Research Foundation, The Composition and methods for creating syngeneic recombinant v irus-producing cells
PT832093E (pt) * 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expressão de lipoproteínas
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
CA2264585C (fr) 1996-08-27 2005-06-14 Chiron Corporation Anticorps monoclonaux definissant des epitopes meningococciques b et leurs utilisations dans la preparation de compositions vaccinales
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de) 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
AU8444698A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into multicelled eukaryo tic organism cells and combination therefor
BR9810500A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Sistema e aparelho para a transferência de ácido nucléico in vivo para o interior de células de organismos eucarióticos pluricelulares
CN1261807A (zh) 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向横纹肌中转移核酸的改进方法和用于实施该方法的组合
AU748973B2 (en) * 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
DE69840508D1 (de) 1997-08-27 2009-03-12 Childrens Hosp Medical Center Molekular-mimetika von meningokokkus b epitopen
US6207775B1 (en) * 1997-08-29 2001-03-27 The Dow Chemical Company Homogeneous filled polymer composite
CA2308606A1 (fr) 1997-11-06 1999-05-20 Chiron S.P.A. Antigenes de neisseria
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
ATE445015T1 (de) * 1998-02-03 2009-10-15 Ct Disease Contr & Prevention Verfahren zur herstellung rekombinanter, lipid- modifizierter psaa proteine und deren verwendung
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261343A3 (fr) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2796148A3 (fr) 1998-05-29 2015-02-25 Novartis Vaccines and Diagnostics, Inc. Combinaison de vaccins de meningitidis B/C
WO2000018355A2 (fr) * 1998-09-30 2000-04-06 Walter Reed Army Institute Of Research Utilisation en tant que vaccin d'invaplex purifie obtenu a partir de bacteries a gram negatif
WO2000018434A1 (fr) 1998-09-30 2000-04-06 American Cyanamid Company Holotoxine mutante du cholera utilisee comme adjuvant
EP1559795A3 (fr) 1998-10-09 2005-11-09 Chiron Corporation Sequences genomiques de neisseria et methode pour leur utilisation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
WO2000042192A1 (fr) 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. POLYPEPTIDES BASB052 DE $i(NEISSERIA MENINGITIDIS)
CA2360658A1 (fr) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Polypeptides antigeniques de neisseria meningitidis, polynucleotides correspondants et anticorps protecteurs
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
PT1154790E (pt) 1999-02-26 2005-03-31 Chiron Srl Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
PT1228217E (pt) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
CN1359426A (zh) 1999-04-30 2002-07-17 希龙公司 奈瑟球菌基因组序列及其用法
CA2929348A1 (fr) * 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Compositions a base de combinaisons de neisseria
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
JP4948731B2 (ja) 1999-12-02 2012-06-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 凍結乾燥の際に生物学的分子を安定化するための組成物および方法
BRPI0107679B8 (pt) * 2000-01-17 2021-05-25 Chiron Spa composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
CN100339482C (zh) * 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
TR200302015T4 (tr) 2000-06-08 2004-01-21 Intercell Biomedizinische Forschungs-Und Entwicklungs Ag İmüno-uyarıcı oligodeoksinükleotitler
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
KR100947751B1 (ko) 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드-단백질 접합체 백신
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CA2441327A1 (fr) 2001-03-30 2002-10-10 Geneprot, Inc. Compositions proteiques humaines riches en arginine-
WO2002083710A2 (fr) 2001-04-13 2002-10-24 Wyeth Holdings Corporation Elimination d'endotoxine bacterienne dans une solution proteique par chromatographie d'affinite metallique immobilisee
ATE455793T1 (de) 2001-04-17 2010-02-15 Novartis Vaccines & Diagnostic Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
CA2449670A1 (fr) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Formes mutantes de l'holotoxine du cholera utilisees comme adjuvant
EP1404368B1 (fr) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Formes mutantes de l'holotoxine du cholera en tant qu'adjuvant
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP2005508630A (ja) 2001-09-14 2005-04-07 インヴィトロジェン コーポレーション Ｄｎａポリメラーゼとその変異体
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
PT1490409E (pt) 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
CN1816350B (zh) 2002-05-14 2010-11-10 莱顿大学 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
EP2351579B1 (fr) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
EP2279746B1 (fr) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (fr) * 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methodes d'augmentation de l'expression de la proteine neisseria et compositions associees
ATE552844T1 (de) 2003-01-30 2012-04-15 Novartis Ag Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
EP1603950A2 (fr) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
MXPA05014171A (es) 2003-06-23 2007-02-21 Sanofi Pasteur Inc Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BR122017002991B1 (pt) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
MXPA06007635A (es) 2003-12-30 2007-01-30 Wyeth Corp Formulaciones de proteinas hidrofobas en una composicion inmunogenica que tiene tolerabilidad mejorada.
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
WO2005105140A2 (fr) 2004-04-30 2005-11-10 Chiron Srl Integration d'une vaccination conjuguee antimeningococcique
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006011060A2 (fr) 2004-07-23 2006-02-02 Chiron Srl Polypeptides pour assemblage oligomere d'antigenes
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CN101107007B (zh) * 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP2008533016A (ja) 2005-03-07 2008-08-21 アイディー バイオメディカル コーポレイション オブ ケベック シー．オー．ビー． アズ グラクソスミスクライン バイオロジカルズ ノース アメリカ 薬学的リポソーム組成物
CN101282984B (zh) 2005-05-06 2013-05-08 诺华疫苗与诊断股份有限公司 A型脑膜炎疫苗的免疫原
SI1896065T2 (sl) 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Postopek za pripravo cepiv
US8007807B2 (en) 2005-09-01 2011-08-30 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
EP2208999B1 (fr) 2005-09-05 2014-08-27 GlaxoSmithKline Biologicals SA Essai d'activité bactéricide sérique pour des antisérums spécifiques de n. méningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
BRPI0620418A2 (pt) 2005-12-23 2011-11-08 Glaxosmithkline Biolog Sa método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
EP2032161B1 (fr) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. Vaccins l3v los
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
MX2008016280A (es) * 2006-06-29 2009-03-26 Novartis Ag Polipeptidos a partir de neisseria meningitidis.
BRPI0715360B8 (pt) 2006-07-27 2022-01-04 Wyeth Corp método para a produção de uma proteína recombinante; método para a produção de uma proteína 2086 meningocócica recombinante (p2086); e composição
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
IN2009KN04098A (fr) 2007-06-04 2015-08-28 Novartis Ag
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20090035328A1 (en) * 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
EP2886551A3 (fr) 2008-02-21 2015-09-23 Novartis AG Polypeptides fHbp méningococciques
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
ES2557282T3 (es) * 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
WO2009143168A2 (fr) 2008-05-19 2009-11-26 Novartis Ag Essais de vaccin
CA2726465A1 (fr) 2008-05-30 2009-12-30 Wendell David Zollinger Vaccin comprenant des vesicules de membrane externe native polyvalent contre des maladies a meningocoques, procede de fabrication et d'utilisation de celui-ci
WO2010027872A1 (fr) 2008-08-27 2010-03-11 Children's Hospital & Research Center At Oakland Dosages fondés sur le facteur h du complément pour déterminer une activité sérique bactéricide contre neisseria meningitidis
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (ja) * 2008-12-15 2014-02-05 川上産業株式会社 梱包箱及び箱状芯材
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2756522C (fr) 2009-03-24 2018-06-26 Novartis Ag Proteine de liaison du facteur h meningococcique utilisee comme adjuvant
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
BRPI1013902A2 (pt) 2009-04-30 2019-09-24 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator quimérico h(fhbp) é método de uso
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
CA2772104A1 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des sequences fhbp a meningocoques
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (ja) * 2009-10-22 2010-03-25 王　文燦 折畳める物置袋
MX2012004850A (es) 2009-10-27 2012-05-22 Novartis Ag Polipeptidos fhbp meningococicos modificados.
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2544712A1 (fr) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Composition immunogène
CA2793510A1 (fr) 2010-03-18 2012-02-16 Novartis Ag Vaccins adjuvantes contre le meningocoque de serogroupe b
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
WO2011161653A1 (fr) 2010-06-25 2011-12-29 Novartis Ag Associations de protéines de liaison du facteur h méningococcique
CN103189071A (zh) 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
WO2012031271A1 (fr) 2010-09-04 2012-03-08 Novartis Ag Dosages d'anticorps bactéricides pour évaluer l'immunogénicité et la puissance de vaccins contre le méningocoque constitués de saccharides capsulaires
EP2613805B1 (fr) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA MENINGOCOQUE SUREXPRIMANT NADA ET/OU NHBA ET DES 
VESICULES DE MEMBRANE EXTERNE DÉRIVÉS DE CELLE-CI
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012032489A1 (fr) 2010-09-10 2012-03-15 Wyeth Llc Variants non-lipidiques des antigènes orf 2086 de neisseria meningitidis
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013229063B2 (en) 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA2903716C (fr) 2013-03-08 2019-04-09 Pfizer Inc. Polypeptides immunogenes de fusion
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
IL161052A0 (en) 2004-08-31
EP2332961B1 (fr) 2016-07-27
IL161052A (en) 2015-04-30
ES2532640T3 (es) 2015-03-30
AU2012202916A1 (en) 2012-06-07
EP2348035B1 (fr) 2015-02-18
ES2561430T3 (es) 2016-02-26
AU2012202916B2 (en) 2013-08-01
JP5997400B2 (ja) 2016-09-28
US20130259889A1 (en) 2013-10-03
AU2012202916C1 (en) 2017-06-08
FR17C1043I1 (fr) 2017-12-22
EP2348034A3 (fr) 2011-09-21
DK2341062T3 (en) 2017-05-08
EP2348036A3 (fr) 2011-08-03
DK2348035T3 (en) 2015-04-20
US20150216960A1 (en) 2015-08-06
MX339524B (es) 2016-05-30
EP2371838A1 (fr) 2011-10-05
US9623101B2 (en) 2017-04-18
EP2341062B1 (fr) 2017-03-29
BRPI0212999B1 (pt) 2020-04-28
CN102755631A (zh) 2012-10-31
IL245956A0 (en) 2016-07-31
ES2609039T3 (es) 2017-04-18
IL233545A0 (en) 2014-08-31
JP2014012002A (ja) 2014-01-23
DK2371836T3 (en) 2017-02-20
HK1178800A1 (zh) 2013-09-19
JP2005515771A (ja) 2005-06-02
EP2371836A1 (fr) 2011-10-05
HK1178429A1 (zh) 2013-09-13
CN1578785B (zh) 2013-03-13
US20120301496A1 (en) 2012-11-29
EP2371837B1 (fr) 2016-09-21
KR20100121699A (ko) 2010-11-18
LUC00041I2 (fr) 2017-12-20
CA2918207C (fr) 2016-10-18
AU2009213040B2 (en) 2012-03-01
IL245955B (en) 2018-01-31
ES2532639T3 (es) 2015-03-30
US20120308595A1 (en) 2012-12-06
DK2343308T3 (en) 2015-03-30
NL300897I2 (nl) 2018-04-06
LUC00042I1 (fr) 2017-10-16
PT2371836T (pt) 2017-02-17
LU92786I2 (fr) 2015-11-02
BE2017C055I2 (fr) 2022-02-01
US20120294880A1 (en) 2012-11-22
CA2939781C (fr) 2022-09-13
IL245956B (en) 2019-02-28
FR17C1043I2 (fr) 2018-12-07
US9168293B2 (en) 2015-10-27
PT2371838E (pt) 2016-03-23
WO2003063766A3 (fr) 2004-01-08
FR17C1042I1 (fr) 2017-12-22
JP5404441B2 (ja) 2014-01-29
CA2918207A1 (fr) 2003-08-07
EP2351767A3 (fr) 2011-09-14
EP2348035A2 (fr) 2011-07-27
CA2849427C (fr) 2016-10-04
PT2343308E (pt) 2015-03-25
ES2562811T3 (es) 2016-03-08
EP1442047A4 (fr) 2005-06-01
KR20110117726A (ko) 2011-10-27
CN102836426B (zh) 2016-09-28
FR15C0056I2 (fr) 2016-06-03
ES2549765T3 (es) 2015-11-02
WO2003063766A2 (fr) 2003-08-07
PT2341062T (pt) 2017-06-02
US20110076299A1 (en) 2011-03-31
EP2351767A2 (fr) 2011-08-03
EP2341063A2 (fr) 2011-07-06
NL300896I1 (nl) 2017-10-20
LUC00042I2 (fr) 2017-12-20
MXPA04003356A (es) 2004-11-29
KR20040066793A (ko) 2004-07-27
FR17C1044I2 (fr) 2018-12-07
KR20100028657A (ko) 2010-03-12
PT2332961T (pt) 2016-09-28
PT2348035E (pt) 2015-03-25
US8563006B2 (en) 2013-10-22
FR17C1042I2 (fr) 2018-12-07
ES2603532T3 (es) 2017-02-28
PT2341063E (pt) 2015-10-29
EP2366707A1 (fr) 2011-09-21
EP1442047B1 (fr) 2016-03-16
EP2366707B1 (fr) 2016-09-21
EP2341063B1 (fr) 2015-08-26
NL300897I1 (nl) 2017-10-20
EP2348034B1 (fr) 2016-11-02
ES2781213T3 (es) 2020-08-31
DK2351767T3 (en) 2015-10-26
PT2351767E (pt) 2015-10-30
CA2463476A1 (fr) 2003-08-07
EP2343308A3 (fr) 2011-07-27
AU2009213040C1 (en) 2012-10-11
DK3199539T3 (da) 2020-04-27
EP2341062A3 (fr) 2011-09-14
EP2332961A2 (fr) 2011-06-15
JP2017025061A (ja) 2017-02-02
LUC00040I2 (fr) 2017-12-20
EP3199539B1 (fr) 2020-03-11
US20170173140A1 (en) 2017-06-22
US20190151431A1 (en) 2019-05-23
AU2009213040A1 (en) 2009-10-08
ES2568895T3 (es) 2016-05-05
PT2348036E (pt) 2016-03-09
EP1442047A2 (fr) 2004-08-04
JP5976880B2 (ja) 2016-08-24
NL300899I1 (nl) 2017-10-20
CA2849427A1 (fr) 2003-08-07
EP2371838B1 (fr) 2015-12-16
NL300896I2 (nl) 2018-04-06
ES2549764T3 (es) 2015-11-02
EP2343308A2 (fr) 2011-07-13
JP2015214545A (ja) 2015-12-03
US20120201844A1 (en) 2012-08-09
AU2018203627A1 (en) 2018-06-07
KR101068318B1 (ko) 2011-09-28
KR101215664B1 (ko) 2012-12-26
US9107873B2 (en) 2015-08-18
EP2351767B1 (fr) 2015-08-26
CA2894296A1 (fr) 2003-08-07
EP3199539A1 (fr) 2017-08-02
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
EP2341062A2 (fr) 2011-07-06
US11116829B2 (en) 2021-09-14
US9757444B2 (en) 2017-09-12
EP2341063A3 (fr) 2011-09-14
EP2343308B1 (fr) 2015-02-18
NL300899I2 (nl) 2018-04-06
CN1578785A (zh) 2005-02-09
JP5923070B2 (ja) 2016-05-24
BRPI0212999B8 (pt) 2021-07-27
ES2603531T3 (es) 2017-02-28
EP2348036A2 (fr) 2011-07-27
IL233545A (en) 2017-10-31
DK2341063T3 (en) 2015-10-26
EP2371837A1 (fr) 2011-10-05
CN102755631B (zh) 2015-11-25
EP2332961A3 (fr) 2011-07-27
CN102836426A (zh) 2012-12-26
JP2010162023A (ja) 2010-07-29
BR0212999A (pt) 2006-05-23
CA2894296C (fr) 2018-05-01
JP2016165275A (ja) 2016-09-15
EP2348035A3 (fr) 2011-09-14
ES2615206T3 (es) 2017-06-05
FR15C0056I1 (fr) 2015-09-11
PT3199539T (pt) 2020-04-01
CA2463476C (fr) 2017-09-12
IL245955A0 (en) 2016-07-31
DK2332961T3 (en) 2016-10-03
DK2371838T3 (en) 2016-02-22
ES2625876T3 (es) 2017-07-20
DK2348036T3 (en) 2016-02-22
US8563007B1 (en) 2013-10-22
KR101099916B1 (ko) 2011-12-28
EP2348034A2 (fr) 2011-07-27
CN105617372A (zh) 2016-06-01
FR17C1044I1 (fr) 2017-12-22
US20060257413A1 (en) 2006-11-16
US8101194B2 (en) 2012-01-24
MX349481B (es) 2017-07-31
ES2593360T3 (es) 2016-12-07
US20120034261A1 (en) 2012-02-09
EP2371836B1 (fr) 2016-12-14
LUC00041I1 (fr) 2017-10-16
CA2939781A1 (fr) 2003-08-07
LUC00040I1 (fr) 2017-10-16
US10300122B2 (en) 2019-05-28
BE2017C057I2 (fr) 2022-02-01
EP2348036B1 (fr) 2015-12-16
US9132182B2 (en) 2015-09-15

Similar Documents

Publication Publication Date Title
BE2022C502I2 (fr)
BE2017C056I2 (fr)
BE2017C051I2 (fr)
BE2017C032I2 (fr)
BE2016C051I2 (fr)
BE2015C046I2 (fr)
BE2014C052I2 (fr)
BE2014C036I2 (fr)
BE2014C026I2 (fr)
BE2014C006I2 (fr)
BE2012C022I2 (fr)
BE2017C050I2 (fr)
BE2011C034I2 (fr)
BE2007C047I2 (fr)
AU2002307149A8 (fr)
JP2001292394A5 (fr)
JP2002164181A5 (fr)
BE2014C008I2 (fr)
BE2016C021I2 (fr)
JP2002233529A5 (fr)
BE2017C059I2 (fr)
BE2012C051I2 (fr)
JP2002192910A5 (fr)
JP2001290171A5 (fr)
JP2002203211A5 (fr)